NorthSea Therapeutics B.V.
NorthSea Therapeutics B.V. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at NorthSea Therapeutics B.V..
NorthSea Therapeutics B.V. is a company.
Key people at NorthSea Therapeutics B.V..
Key people at NorthSea Therapeutics B.V..
NorthSea Therapeutics B.V. is a late-stage clinical biotechnology company headquartered in the Netherlands, developing structurally engineered fatty acids (SEFAs) as oral, once-daily therapies for metabolic, cholestatic, and fibrotic liver diseases. It targets unmet needs in conditions like metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), intestinal failure-associated liver disease (IFALD), and severe hypertriglyceridemia (sHTG). Key pipeline assets include icosabutate (Phase 2b completed for MASH, showing histological improvements), orziloben (Phase 2 for IFALD), and SEFA-1024 (Phase 3 for sHTG), serving patients with limited treatment options, such as those on prolonged parenteral nutrition or with diabetic MASH.[1][4][5]
The company demonstrates strong growth momentum through recent milestones: positive Phase 2b ICONA trial results for icosabutate published in March 2025, leadership expansions in February 2025, and an $80M Series C financing round co-led by Ysios Capital and Forbion Growth.[1][2]
NorthSea Therapeutics emerged from innovative research into fatty acid signaling pathways, focusing on structural modifications to create SEFAs that target liver and gut receptors without systemic distribution or energy utilization.[1][5] While specific founding year and founders are not detailed in available sources, the company is backed by prominent investors including Ysios Capital, Forbion Growth/Ventures, Novo Holdings, venBio Partners, Sofinnova, BGV, and New Science Ventures, indicating early traction through scientific validation.[2][4]
Pivotal early moments include preclinical studies (e.g., 2018 AASLD/EASL posters on icosabutate's anti-inflammatory effects) and clinical advancements like the Phase 2a dosing of orziloben for IFALD, plus FDA Rare Pediatric Disease Designation for SEFA-6179 (orziloben).[3][5] Leadership under CEO Rob de Ree, CSO David Fraser, and a team of industry veterans and advisors like Prof. Arun Sanyal and Prof. Scott L. Friedman has driven evolution from NASH focus to a broader metabolic disease pipeline.[6]
NorthSea rides the exploding demand for MASH/NASH therapies, a market affecting millions amid rising metabolic diseases, where few approved options exist—especially for diabetic patients or orphans like IFALD.[1][4] Timing aligns with 2025 trial readouts and regulatory shifts (e.g., MASH nomenclature change, FDA designations), amplified by post-pandemic focus on liver health from obesity/diabetes epidemics.[1][3]
Market forces favor its SEFA approach: oral convenience beats injectables, dual receptor agonism tackles multifactorial pathology (inflammation, fibrosis, lipids), and biotech funding resurgence supports late-stage biotechs.[2][5] NorthSea influences the ecosystem by validating fatty acid engineering, publishing in high-impact journals (e.g., Journal of Hepatology), and presenting at ASPEN/AASLD, potentially enabling combo therapies in a field ripe for innovation.[1][5]
NorthSea is poised for Phase 3 data readouts in 2026+ (SEFA-1024) and potential MASH partnerships/approvals for icosabutate, leveraging its de-risked assets and recent financing for commercialization.[1][2] Trends like AI-driven drug design and precision metabolic therapies will accelerate SEFA optimization, while expanding indications (e.g., broader fibrosis) could position it as a backbone player.
Its influence may evolve from pipeline innovator to category leader if histology data holds, tying back to its core mission: delivering targeted, convenient therapies where liver diseases urgently need breakthroughs.[1][4]
